European Urology Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Clinical significance of alpha 2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naive men with elevated PSA level. 2022
• Effect of 18F-DCFPyL PET/CT (=PSMA PET) on the management of patients with suspected limited residual/recurrent disease following radical prostatectomy: Results of a prospective, multicenter registry trial 2022
• Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study 2021
• Benefits and harms of Botulinum Toxin-A in the treatment of chronic pelvic pain syndromes: Systematic review by the EAU Chronic Pelvic Pain Panel 2021
• Effectiveness of interventions in patients who develop graft nephrolithiasis after kidney transplantation: A systematic review 2021
• Surgical treatment in ischaemic and non-ischaemic priapism: A systematic review 2021
• Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).  84:361-370. 2023
• Optimizing Treatment Selection in Advanced Renal Cell Carcinoma via IMDC Risk Group Stratification.  84:379-380. 2023
• Reply to Badar M. Mian. Prostate Biopsy: Hyperbole and Misrepresentation Versus Scientific Evidence and Equipoise. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.039.  S0302-2838(23)03100-7. 2023
• Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.  84:109-116. 2023
• Corrigendum to “Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma” [Eur Urol 2023].  83:e166-e167. 2023
• Comparing treatment outcomes for fluoroscopic and fluoroscopy-free endourological procedures: A systematic review on behalf of the EAU urolithiasis guidelines panel.  83:S1436-S1437. 2023
• Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.  82:182-192. 2022
• Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy.  81:337-346. 2022
• Clinical significance of α2,3-sialylated prostate-specific antigen density and MRI for high-grade prostate cancer in biopsy-naïve men with elevated PSA level..  81:S729-S731. 2022
• Effect of 18F-DCFPyL PET/CT (=PSMA PET) on the management of patients with suspected limited residual/recurrent disease following radical prostatectomy: Results of a prospective, multicenter registry trial.  81:S299-S299. 2022
• A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer.  80:531-545. 2021
• Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.  80:374-382. 2021
• Re: Rachel M. Glicksman, Ur Metser, Douglass Vines, et al. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. Eur Urol 2021;80:374–82.  80:e77-e78. 2021
• Free Graft Augmentation Urethroplasty for Bulbar Urethral Strictures: Which Technique Is Best? A Systematic Review.  80:57-68. 2021
• A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms.  79:796-809. 2021
• Benefits and harms of conservative, pharmacological, and surgical management options for women with bladder outlet obstruction: A systematic review from the European Association of Urology non-neurogenic female LUTS guidelines panel.  79:S437-S438. 2021
• Management of women with overactive bladder syndrome: A systematic review with meta-analysis of benefits and potential harms of surgical and non-surgical treatment options by the EAU non-neurogenic female LUTS Guidelines panel.  79:S439-S440. 2021
• What are the different diagnostic tests for female Bladder Outlet Obstruction (fBOO)? A systematic review from the European Association of Urology non-neurogenic female LUTS Guidelines Panel.  79:S435-S436. 2021
• European Association of Urology Position Paper on the Prevention of Infectious Complications Following Prostate Biopsy.  79:11-15. 2021
• Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.  78:834-844. 2020
• An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting.  78:546-569. 2020
• Baseline Risks of Venous Thromboembolism and Major Bleeding are Crucial in Decision-making on Thromboprophylaxis.  78:369-370. 2020
• Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.  77:614-627. 2020
• Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.  77:311-317. 2020
• Response of Primary Renal Cell Carcinoma to Systemic Therapy.  76:852-860. 2019
• Treatment of Bladder Stones in Adults and Children: A Systematic Review and Meta-analysis on Behalf of the European Association of Urology Urolithiasis Guideline Panel.  76:352-367. 2019
• Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.  75:967-987. 2019
• Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis.  75:788-798. 2019
• Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.  75:853-860. 2019
• Benefits of Empiric Nutritional and Medical Therapy for Semen Parameters and Pregnancy and Live Birth Rates in Couples with Idiopathic Infertility: A Systematic Review and Meta-analysis.  75:615-625. 2019
• Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.  75:100-110. 2019
• Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.  75:300-309. 2019
• Risks and Benefits of Adjuvant Radiotherapy After Inguinal Lymphadenectomy in Node-positive Penile Cancer: A Systematic Review by the European Association of Urology Penile Cancer Guidelines Panel.  74:76-83. 2018
• Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel.  73:394-405. 2018
• Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology.  73:290-300. 2018
• Procedure-specific Risks of Thrombosis and Bleeding in Urological Cancer Surgery: Systematic Review and Meta-analysis.  73:242-251. 2018
• Procedure-specific Risks of Thrombosis and Bleeding in Urological Non-cancer Surgery: Systematic Review and Meta-analysis.  73:236-241. 2018
• The Risk of Tumour Recurrence in Patients Undergoing Renal Transplantation for End-stage Renal Disease after Previous Treatment for a Urological Cancer: A Systematic Review.  73:94-108. 2018
• Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel.  72:865-868. 2017
• Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review.  72:869-885. 2017
• Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non–muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.  72:801-813. 2017
• What are the Benefits and Harms of Ureteroscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review.  72:772-786. 2017
• Reply to Philipp Dahm, Vikram Narayan, and Jae Hung Jung's Letter to the Editor re: Richard J. Sylvester, Steven E. Canfield, Thomas B.L. Lam, et al. Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. Eur Urol 2017;71:811–9.  72:e93-e94. 2017
• Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606–17.  72:e59-e60. 2017
• Tract Sizes in Miniaturized Percutaneous Nephrolithotomy: A Systematic Review from the European Association of Urology Urolithiasis Guidelines Panel.  72:220-235. 2017
• What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.  72:250-266. 2017
• The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.  72:84-109. 2017
• Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree.  71:811-819. 2017
• Sentinel Node Procedure in Prostate Cancer: A Systematic Review to Assess Diagnostic Accuracy.  71:596-605. 2017
• Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.  70:1052-1068. 2016
• Incidence and Remission of Nocturia: A Systematic Review and Meta-analysis.  70:372-381. 2016
• Long-term Impact of Mode of Delivery on Stress Urinary Incontinence and Urgency Urinary Incontinence: A Systematic Review and Meta-analysis.  70:148-158. 2016
• Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.  69:980-983. 2016
• Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer — At What Cost? Eur Urol 2016;69:642–44.  69:644-645. 2016
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.  69:634-641. 2016
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma..  69:634-641. 2016
• The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.  69:624-633. 2016
• Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer.  69:177-178. 2016
• Words or Wisdom: Re: The Incidence and Relative Risk of Cardiovascular Toxicity in Patients Treated with New Hormonal Agents for Castration-resistant Prostate Cancer..  69:177-178. 2016
• What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women.  65:1211-1217. 2014
• The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer.  65:3-6. 2014
• Comorbidity Status Does Not Independently Predict Survival Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.  64:518-519. 2013
• Immediate Post–Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non–Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review.  64:421-430. 2013
• Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials.  63:717-723. 2013
• Cost Effectiveness of Treatment Options for Early Prostate Cancer: Can We Put the Puzzle Pieces Together?.  63:411-412. 2013
• Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer.  61:363-369. 2012
• Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2012;61:363–9.  61:e4-e5. 2012
• Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience.  59:556-562. 2011
• Re: Gunnar Aus, Christopher Chapple, Tomas Hanûs, et al. The European Association of Urology (EAU) Guidelines Methodology: A Critical Evaluation. Eur Urol 2009;56:859–64.  56:e21-e22. 2009
• Systematic Review and Meta-Analysis of Robotic-Assisted versus Conventional Laparoscopic Pyeloplasty for Patients with Ureteropelvic Junction Obstruction: Effect on Operative Time, Length of Hospital Stay, Postoperative Complications, and Success Rate.  56:848-858. 2009
• Testosterone and Prostate Cancer: Revisiting Old Paradigms.  56:48-56. 2009
• Editorial Comment on: Metastin Inhibits Migration and Invasion of Renal Cell Carcinoma with Overexpression of Metastin Receptor.  55:450-451. 2009
• Lower Plasma Adiponectin Levels Are Associated with Larger Tumor Size and Metastasis in Clear-Cell Carcinoma of the Kidney.  54:866-874. 2008
• Editorial Comment on: Photodynamic Diagnosis in Urology: State-of-the-Art.  53:1149-1150. 2008

has subject area

• 1103 Clinical Sciences (FoR)
• Urology & Nephrology (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0302-2838

Electronic International Standard Serial Number (EISSN)

• 1873-7560